Original Article

[^68Ga]Ga-NODAGA-E[(cRGDyK)]_2 PET and hyperpolarized [1-13C] pyruvate MRSI (hyperPET) in canine cancer patients: simultaneous imaging of angiogenesis and the Warburg effect

Andreas Clemmensen¹ · Adam E Hansen¹ · Pernille Holst² · Christina Schoier² · Sissel Bisgaard¹ · Helle H Johanssens¹ · Jan Henrik Ardenkjæer-Larsen³ · Annemarie T Kristensen² · Andreas Kjaer¹

Received: 7 February 2020 / Accepted: 19 May 2020

Abstract

Purpose Cancer has a multitude of phenotypic expressions and identifying these are important for correct diagnosis and treatment selection. Clinical molecular imaging such as positron emission tomography can access several of these hallmarks of cancer non-invasively. Recently, hyperpolarized magnetic resonance spectroscopy with [1-13C] pyruvate has shown great potential to probe metabolic pathways. Here, we investigate simultaneous dual modality clinical molecular imaging of angiogenesis and deregulated energy metabolism in canine cancer patients.

Methods Canine cancer patients (n=11) underwent simultaneous[^68Ga]Ga-NODAGA-E[(cRGDyK)]_2 (RGD) PET and hyperpolarized [1-13C]pyruvate-MRSI (hyperPET). Standardized uptake values and [1-13C]lactate to total 13C ratio were quantified and compared generally and voxel-wise.

Results Ten out of 11 patients showed clear tumor uptake of[^68Ga]Ga-NODAGA-RGD at both 20 and 60 min after injection, with an average SUV_{mean} of 1.36 ± 0.23 g/mL and 1.13 ± 0.21 g/mL, respectively. A similar pattern was seen for SUV_{max} values, which were 2.74 ± 0.41 g/mL and 2.37 ± 0.45 g/mL. The [1-13C]lactate generation followed patterns previously reported. We found no obvious pattern or consistent correlation between the two modalities. Voxel-wise tumor values of RGD uptake and lactate generation analysis revealed a tendency for each canine cancer patient to cluster in separated groups.

Conclusion We demonstrated combined imaging of[^68Ga]Ga-NODAGA-RGD-PET for angiogenesis and hyperpolarized [1-13C]pyruvate-MRSI for probing energy metabolism. The results suggest that[^68Ga]Ga-NODAGA-RGD-PET and [1-13C]pyruvate-MRSI may provide complementary information, indicating that hyperPET imaging of angiogenesis and energy metabolism is able to aid in cancer phenotyping, leading to improved therapy planning.

Keywords Positron emission tomography · Hyperpolarized magnetic resonance spectroscopy imaging · [1-13C]pyruvate · Angiogenesis-PET · ^68Ga-RDG · Cancer · hyperPET · Glycolysis

Introduction

Cancer is responsible for more than one-third of years lost, and the rate is rising [1]. Cancer covers a multitude of mutations, each a disease in itself, and in an effort to generalize the common traits, Hanahan and Weinberg formulated ten hallmarks of cancer [2]. Several of the hallmarks can be accessed by clinical molecular imaging, such as positron emission tomography (PET). One of these is deregulated cellular energetics, also simply known as the Warburg effect [3], which is routinely exploited in the clinic by PET with the glucose analog 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) to diagnose and stage cancer disease. Other hallmarks can be assessed using other PET tracers, such as 3-deoxy-3-[18F]fluorothymidine
(\([^{18}\text{F}]\text{FLT}\)) for proliferation and \([^{68}\text{Ga}]\text{Ga-NODAGA-E[\text{cRGDyK}]_2}\) (RGD) for angiogenesis.

Hyperpolarized \(^{13}\text{C}\) magnetic resonance spectroscopic imaging (MRSI) is a non-invasive molecular imaging modality, which is currently entering clinical use \([4–7]\). Here, the technique of dissolution dynamic nuclear polarization (dDNP) overcomes the inherently low sensitivity of MRI by increasing the \(^{13}\text{C}\) signal by 5 orders of magnitude \([8]\). Hyperpolarized \(^{13}\text{C}\)-MRSI with \([^{1-13}\text{C}]\text{pyruvate}\) can be utilized to interrogate the Warburg effect, where the deregulated cellular energetics with an elevated aerobic glycolysis is reflected by the appearance of \([^{1-13}\text{C}]\text{lactate}\) \([9–14]\). Integrated PET/MRI allows for simultaneous \([^{18}\text{F}]\text{FDG-PET}\) and hyperpolarized \([^{1-13}\text{C}]\text{pyruvate-MRSI}\) in the hyperPET setup \([15, 16]\). Comparison studies show a general spatial concurrence between patterns of FDG uptake and lactate generation \([17, 18]\), as well as a correlation between values of \([^{18}\text{F}]\text{FDG uptake and lactate generation}\) \([19, 20]\), but with an apparent tumor type dependence, which we hypothesized may allow for a more specific metabolic profiling of the deregulated cellular energetics using hyperPET \([20]\).

In the present work, we expand the hyperPET approach to include imaging of another key hallmark of cancer, angiogenesis. During cell proliferation, the surrounding extra-cellular matrix (ECM) is remodeled, and in this process, integrins are essential cell adhesion receptors \([21, 22]\). One subtype, integrin \(\alpha_\text{v}\beta_3\), is expressed in newly formed endothelial cells of the vasculature, and the experimental, in-house developed, PET tracer \([^{68}\text{Ga}]\text{Ga-NODAGA-E[\text{cRGDyK}]_2}\) (RGD) binds to this receptor \([23–25]\). Integrin \(\alpha_\text{v}\beta_3\) is overexpressed in several types of cancer \([26]\), and identifying these can lead to improved treatment, e.g., higher predictability of anti-angiogenic therapy. Imaging of angiogenesis using RGD as the integrin \(\alpha_\text{v}\beta_3\) antagonist first started with \([^{18}\text{F}]\text{Galacto-RGD}\) \([27, 28]\). With the introduction of the \(^{68}\text{Ge/68Ga}\) generator, chelation chemistry enabled fast and relatively stable labelling. Several chelators have been used \([29–32]\), with dimeric NODAGA emerging as an attractive compromise between affinity and stability \([33, 34]\). Combined with the relatively short half-life of \(^{68}\text{Ga}\), these factors make an evaluation of angiogenesis by temporal uptake of \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) relevant.

While \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD-PET}\) and hyperpolarized \([^{1-13}\text{C}]\text{pyruvate-MRSI}\) have been extensively examined and validated individually \([24, 33, 35–37]\), the two molecular imaging modalities have not been compared in a realistic, clinically relevant model. This hyperPET combination could thus, provide simultaneous clinical imaging of angiogenesis and tumor energy metabolism and be utilized to investigate a possible relationship between those hallmarks of cancer as well as selection of treatment regime. In cancerous hypoxic tissue, angiogenesis is induced, and cells will switch to anaerobic metabolism, leading to the basic hypothesis that the \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) uptake and \([^{1-13}\text{C}]\text{lactate generation}\) are correlated.

Here, we investigate the combined molecular imaging of angiogenesis by \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD-PET}\) and deregulated energetics by hyperpolarized \([^{1-13}\text{C}]\text{pyruvate MRSI}\) in canine patients with spontaneous cancers. The overall aim was to evaluate whether hyperPET can evaluate angiogenesis and tumor metabolism simultaneously in canine cancer patients prior to human clinical use. More specifically, we compare general tumor angiogenesis as demonstrated by \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) uptake with lactate generation, including patterns of tumor uptake heterogeneity between the modalities.

**Materials and methods**

**Canine cancer patients**

All procedures were approved by the Ethics and Administrative Committee, Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen. Canine cancer patients \((n = 11)\) were included in the study after solid cancer had been verified by histopathology and where advanced tumor imaging could provide important information affecting the further treatment. On the day of examination, the patient received an intramuscular injection of methadone (Comfortan, 0.2 mg/kg) and two intravenous catheters were placed on separate extremities by experienced clinical veterinary staff. Upon arrival to the imaging facility, the canine cancer patient received an intravenous injection of diazepam (DAK, 0.5 mg/kg). Anesthesia was induced with a bolus injection of propofol (PropoVet, 4 mg/kg); the patient was intubated, connected to a ventilator, and supplied with oxygen and 2–3% Sevoflurane. The heart rate, oxygen saturation, and blood pressure were monitored throughout the procedure.

**\([^{1-13}\text{C}]\text{pyruvate sample preparation}\)**

\([^{1-13}\text{C}]\text{pyruvic acid}\) (Sigma Aldrich, Denmark) was mixed with an electron paramagnetic agent (AH111501, Syncom) to a concentration of 15 mM. One milliliter of this solution was hyperpolarized in a 5 T SpinLab clinical polarizer (GE Healthcare, Denmark) for approximately 2 h, before being dissolved in 40 mL 0.1 mM EDTA dissolution media and neutralized in 14.6 mL buffer to a final concentration of 250 mM \([^{1-13}\text{C}]\text{pyruvate}\).

**\([^{68}\text{Ga}]\text{Ga-NODAGA-E[\text{cRGDyK}]_2}\) synthesis**

Labeling of NODAGA-E[\(\text{cRGDyK}\)]\(_2\) (ABX GmbH) was performed using a Modular-Lab PharmTracer (Eckert &
Ziegler). The $^{68}$Ge/$^{68}$Ga generator (IGG100; Eckert & Ziegler) was eluted with 6 mL of 0.1 M HCl. The eluate was concentrated on a Strata-XC cartridge and eluted with 700 μL of NaCl/HCl. Then, 30 nmol of NODAGA-E[(cRGDyK)]$_2$ dissolved in 50 μL of TraceSelect water was labeled in 1000 μL of 1.4 M NaOAc buffer pH 4.5, and 400 μL of 50% EtOH at 60 °C for 5 min. The final product $[^{68}$Ga]$\text{Ga-NODAGA-E[(cRGDyK)]}_2$, was purified on a SepPak tC2 plus cartridge (Waters), eluted with 50% ethanol, and formulated with isotonic saline to a total volume of 9 mL. The resulting yield was 501 ± 106 MBq of $[^{68}$Ga]$\text{Ga-NODAGA-E[(cRGDyK)]}_2$ for each production with a radiochemical purity ≥ 98%.

For quality control analysis, a high-performance liquid chromatograph (Ultimate 3000; Dionex) was performed on a Kinetex C18 column (2.6 μm, 100 Å, 50 × 4.6 mm; Phenomenex) and with the UV and radio-detector connected in series. The mobile phases were eluent A, 0.1% trifluoroacetic acid in H$_2$O, and eluent B, 0.1% trifluoroacetic acid in MeCN. For thin-layer chromatography, a ScanRam scanner and iTLC-SG plates (Agilent Technologies) were used. The mobile phase was 77 g/L ammonium acetate in water/methanol (1:1). For gas chromatography, a Shimadzu GC2014 was used with a Zebron ZB-WAX 30 m × 0.53 mm × 1.00 μm column.

**Imaging protocol**

All imaging was acquired using a combined clinical PET/MR scanner (mMR Biograph, Siemens) and a dual-tuned $^1$H/$^13$C transmit/receive flex surface coil (RAPID Biomedical, Germany) placed over the primary tumor.

Localizer images were followed by relevant anatomical $^1$H T1- (TSE; TR 4000 ms, TE 89 ms, voxel size, 0.6 × 0.5 × 3.0 mm; 19 slices) and T2- (TSE; TR 550 ms, TE 6.5 ms, voxel size 0.7 × 0.6 × 3.0 mm; 27 slices) weighted MR imaging.

A single-bed, 5 min PET acquisition was performed 20 and 60 min after intravenous injection of 8.0 MBq/kgBW of $[^{68}$Ga]$\text{Ga-NODAGA-E[(cRGDyK)]}_2$, corresponding to 0.713 ± 0.19 μg/kgBW peptide. Between the two PET time points, $^{13}$C-MRSI was performed. The primary sequence was a $^{13}$C CSI acquired 30–45 s after injection of 0.58 mL/kgBW hyperpolarized $[^{13}$C]pyruvate solution (CSI; TR 80 ms, flip angle 10°, bandwidth 10 kHz, FOV 80–160 mm, slice thickness 13 mm, matrix 16 × 16 [circular truncation], acquisition time 11 s). The field of view was adjusted according to the organ of interest. After all other imaging sequences was completed, a transverse fat-saturated T1-weighted TSE with the same parameters as the first T1 TSE was performed 4–5 min after 0.1 mL/kgBW gadolinium injection (Gadovist) in seven of the patients.

**PET reconstruction**

$[^{68}$Ga]$\text{Ga-NODAGA-RGD-PET}$ was reconstructed using vendor supplied OP-OSEM3D with 4 iterations and 21 subsets into a 344 × 344 matrix size and with a 4 mm Gaussian filter applied. Due to the limited sensitivity profile of the MR surface coil used, the MR-generated 511 keV attenuation maps were inadequate for correct PET quantification and were manually corrected based on the body outline in the uncorrected PET image [38]. The attenuation map correction was performed using the MINC toolbox software [39] and returned to the original DICOM container for correct reconstruction. The correction method was validated by comparing corrected attenuation maps to complete attenuation maps made using the scanner body coil, which was available for some patients only.

**Image quantification**

Regions of interest (ROI) were delineated on anatomical MRI, primarily the contrast-enhanced, fat-saturated T1-weighted TSE, by an experienced radiologist. It was attempted to avoid vessels and major areas of necrosis, before copying the ROI to functional imaging.

**$^{13}$C-MRSI quantification**

The area of $[^{1-13}$C]pyruvate, $[^{1-13}$C]lactate, $[^{1-13}$C]alanine, and $[^{1-13}$C]pyruvate hydrate peaks were quantified using a general linear model implemented in Matlab (The MathWorks) and applied in the time domain. When reporting a metabolite ratio, the normalization was performed to the sum of all modeled peak areas. For visualization of the $[^{1-13}$C]lactate to total $^{13}$C ratio, voxels which had a pyruvate peak height larger than five times the standard deviation of the noise in a background region of the spectrum were used and interpolated to the anatomical MRI resolution.

**Voxel-wise comparison of PET and CSI**

For the purpose of a voxel-wise comparison, PET images (voxel size 2.1 × 2.1 × 2.0 mm$^3$) were resampled to the MRSI (voxel size 5.0 × 7.5 × 5.0–10.0 × 13 mm$^3$). Resampling was performed using scripts based on MINC [39]. The voxel-wise comparison was carried out for MRSI voxels with at least 90% of their volume within the radiologist-defined ROI.

**Statistics**

All statistical tests were performed in Prism (version 8.3, Graphpad, La Jolla), and results presented with standard error of the mean. All comparisons were performed using standard
parametric, two-tailed \( t \) tests. Values of \( p < 0.05 \) were considered statistically significant.

**Results**

Eleven canine cancer patients were included. All patients underwent \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD PET} \) at two timepoints (18 ± 1 min, range [7; 22] and 60 ± 2 min, range [53; 67]) and seven of these were also imaged using hyperpolarized \([1-^{13} \text{C}] \text{pyruvate MRSI} \). For one patient, the exam had to be aborted prior to the MRSI procedure due to anesthetic complications, and for the remaining three patients, the polarizer was unavailable due to maintenance or technical failure. An overview of patient characteristics can be found in Table 1. Figure 1 shows an example of the hyperPET exam for patient 1.

\[ ^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET tumor uptake shows little time dependence} \]

Patients \((n = 11)\) showed varying degrees of \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD PET} \) uptake in tumors, with an average \( \text{SUV}_{\text{mean}} \) of 1.36 ± 0.23 g/mL and 1.13 ± 0.21 g/mL at early and late imaging time points, respectively (Fig. 2). A similar pattern was seen for \( \text{SUV}_{\text{max}} \) values, which were 2.74 ± 0.41 g/mL and 2.37 ± 0.45 g/mL. The changes correspond to a drop of 16.1% \((p = 0.012, \text{paired } t\text{-test})\) for \( \text{SUV}_{\text{mean}} \) and 12.4% \((p = 0.056, \text{paired } t\text{-test})\) for \( \text{SUV}_{\text{max}} \).

\[ ^{68} \text{Ga}] \text{Ga-NODAGA-RGD uptake and \( ^{13} \text{C} \)-lactate ratio in tumors across patients are not related} \]

A scatter plot of maximum \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD tumor uptake} \) and lactate generation across patients is shown in Fig. 3. Tumors show a wide range of both RGD uptake (SUV 1–6) and lactate ratio (0.2–0.8). We found no direct pattern or correlation between the two modalities across patients, or across cancer types as was shown by Hansen et al. \[20\].

Both \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD PET and \( ^{13} \text{C} \)-pyruvate MRSI show heterogeneous tumor uptake} \]

Figure 4 shows spectroscopic imaging of lactate to total \( ^{13} \text{C} \) ratio from \( ^{13} \text{C} \) MRSI together with \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD PET} \) for all seven complete hyperPET examinations. Summarizing the trends overall, both lactate ratio and \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD PET} \) uptake display a heterogeneous pattern of enhancement in tumors. The individual patients are discussed in more detail below.

The tumor of patient #1 (soft tissue sarcoma) generally has high values for both \([1-^{13} \text{C}] \text{lactate to total } ^{13} \text{C} \text{ MRSI} \) and \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD uptake} \), both primarily confined to the tumor. The tumor appears anatomically heterogeneous, possibly with very small areas of necrosis (white star, Fig. 4(1a)). Also, intra-tumoral lactate ratio and \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD distribution appears heterogeneous, without a clear spatial correspondence between} \]

\([^{68} \text{Ga}] \text{Ga-NODAGA-RGD PET and \([1-^{13} \text{C}] \text{lactate to total } ^{13} \text{C} \text{ MRSI} \). Pyruvate is primarily seen in major vasculature (thin arrow, Fig. 4(1d)), and the cavity in the top region, presumably an encapsulated fluid collection due to a biopsy performed prior to the scanning session (thick arrow, Fig. 4(1d)).

The tumor of patient #2 (malignant melanoma) appears anatomically homogenous and generally shows very little tumor signal for both modalities, except some \([1-^{13} \text{C}] \text{lactate in a few pixels. There is a relatively high uptake of} \]

\([^{68} \text{Ga}] \text{Ga-NODAGA-RGD in the soft tissue of the paw} \) (white arrows, Fig. 4(2b)).

| ID | Weight (kg) | Tumor type | Tumor location | Imaging |
|----|-------------|------------|----------------|--------|
| 1  | 26          | Soft tissue sarcoma | Humerus | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 2  | 34          | Malignant melanoma  | Ungual   | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 3  | 41          | Osteosarcoma       | Femur    | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 4  | 27          | Ectopic follicular thyroid carcinoma with osseous metaplasia | Basilytoid | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 5  | 28          | Soft tissue sarcoma | Humerus | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 6  | 30          | Thyroid carcinoma | Gl. thyroidea | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 7  | 34          | Thyroid carcinoma | Gl. thyroidea | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET + [1-^{13} \text{C}]pyruvate CSI} \) |
| 8  | 43          | Thyroid carcinoma | Gl. thyroidea | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET} \) |
| 9  | 32          | Chondrosarcoma     | Ulna     | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET} \) |
| 10 | 21          | Thyroid carcinoma | Gl. thyroidea | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET} \) |
| 11 | 22          | Ectopic follicular thyroid carcinoma | Regio laryngea | \([^{68} \text{Ga}] \text{Ga-NODAGA-RGD-PET} \) |
The tumor of patient #3 (osteosarcoma) shows a heterogeneous \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) uptake around the central bone region (green outline). The \([^{1-13}\text{C}]\text{lactate to total }^{13}\text{C}\) ratio also appears spatially heterogeneous and shows some visual concurrence with the RGD distribution. Pyruvate is primarily seen in a major blood vessel along the edge of the tumor (white arrow, Fig. 4(3d)).

The tumor in patient #4 (thyroid carcinoma) shows a very heterogeneous distribution for both modalities, which corresponds with the follicular nature of the anatomical imaging. There appears to be no correlation between modalities, with a tendency of high \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) uptake at superficial tumor area, whereas high \([^{1-13}\text{C}]\text{lactate to total }^{13}\text{C}\) ratio occurs more centrally.

The subcutaneous tumor in patient #5 (soft tissue sarcoma) appears to have an area of central necrosis (white arrow, Fig. 4(5a)). \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) uptake is high in the vital tumor tissue, whereas \([^{1-13}\text{C}]\text{lactate to total }^{13}\text{C}\) ratio appears more evenly distributed.

The tumor in patient #6 (thyroid carcinoma) is highly vascularized with a large area of central necrosis (excluded from ROI, white star, Fig. 4(6a)). \([^{68}\text{Ga}]\text{Ga-NODAGA-RGD}\) and \([^{1-13}\text{C}]\text{lactate to total }^{13}\text{C}\) ratio are distributed heterogeneously in the tumor, with high spatial concurrence. Both \([^{1-13}\text{C}]\text{pyruvate and }[^{1-13}\text{C}]\text{lactate is primarily seen in the ventral tumor region (white arrow, Fig. 4(6d)), but overall, the }^{13}\text{C}\) signal is potentially affected by the MR coil sensitivity profile.
The tumor in patient #7 (thyroid carcinoma) is clearly delineated, confined within the capsule and exhibits a necrotic core. Both $^{68}$Ga-NODAGA-RGD uptake and $[1-^{13}C]$lactate to total $^{13}C$ ratio is seen in the vital tumor tissue, the latter again influenced by the MR coil sensitivity profile. Intra-tumoral heterogeneity of $^{68}$Ga-NODAGA-RGD and $[1-^{13}C]$lactate to total $^{13}C$ ratio distribution are not related in general.

The spatial relation of $^{68}$Ga-NODAGA-RGD uptake and $[1-^{13}C]$lactate generation in tumors was further studied by a voxel-wise analysis, with results shown in Table 2. Voxels were only included if 90% of the voxel was inside the radiologist-delineated ROI. Tumors in patients #2 and #5 are omitted from further discussion due to poor $^{13}C$ signal and small number of relevant voxels. Of the remaining five tumors, $^{68}$Ga-NODAGA-RGD uptake and $[1-^{13}C]$lactate to total $^{13}C$ ratio were weakly and non-significantly correlated in three, a significant positive correlation was observed for the tumor in patient #6, and a significant negative correlation was observed for the tumor in patient #7. A similar pattern was seen for the voxel-wise correlation of $^{68}$Ga-NODAGA-RGD uptake and $[1-^{13}C]$lactate (not normalized to total $^{13}C$), with non-significant correlation in two tumors, a significant positive correlation in tumors of patients #3 and #6, and a significant negative correlation for the tumor in patient #4.

$[1-^{13}C]$pyruvate metabolism showed no systematic relation with $^{68}$Ga-NODAGA-RGD-PET across tumors

Figure 5 shows $^{68}$Ga-NODAGA-RGD-PET uptake [SUV (g/mL)] versus $[1-^{13}C]$lactate to total $^{13}C$ ratio in all tumor voxels for all patients. There is no apparent relation between angiogenesis and metabolism across tumors, as was also observed for the maximum values of RGD uptake and lactate ratio in Fig. 3. Please note that due to partial volume effects of the resampling of PET to $^{13}C$-MRSI voxels, RGD uptake values are systematically lower than in Fig. 2.

Lines are shown for within-tumor significant voxel-wise correlation of RGD uptake and $^{13}C$-lactate ratio. Both positive and negative correlations tend to appear for low values of the lactate ratio.

Within each patient tumor, the range of RGD uptake and $^{13}C$-lactate ratio is smaller, or much smaller, than the range of values across all patient tumors. Apparently, tumor voxel values of RGD uptake and $[1-^{13}C]$lactate to total $^{13}C$ ratio in Fig. 5 tend to group in clusters for each patient tumor. For tumors in patients #1, #2, #3, and #6, the clusters have small overlap between patients. Tumors in patients #4, #5, and #7 show some overlap of both RGD uptake and lactate ratio, with relatively small values of RGD uptake (approximately 0.3–0.7 SUV) and lactate ratio (approximately 0.1–0.3).

Discussion

In the present work, we demonstrated the combined $^{68}$Ga-NODAGA-RGD-PET for angiogenesis and hyperpolarized $[1-^{13}C]$pyruvate-MRSI for probing energy metabolism in a single session. Both RGD uptake and $[1-^{13}C]$lactate generation showed a large degree of heterogeneity across tumor types and spatially within tumors. We found no obvious pattern of relation or consistent correlation between the two molecular imaging modalities. As illustrated in Fig. 5, the tumor voxel values of RGD uptake and lactate ratio for each canine cancer patient tends to aggregate in separated groups, indicating that $^{68}$Ga-NODAGA-RGD-PET and hyperpolarized $[1-^{13}C]$pyruvate-MRSI may provide complementary cancer phenotypic information.
[68Ga]Ga-NODAGA-RGD-PET showed general tumor uptake in 10 out of 11 canine patients, with a varying degree of heterogeneity, indicating the disordered angiogenesis and vasculature present in cancer. Uptake values [SUV] varied across cancer types, although no pattern was seen in this regard. PET image contrast may potentially be affected by several factors, such as blood clearance, tumor vasculature, receptor dynamics, stability of the chelator, and radionuclide decay. Uptake values in the present study showed a significant, albeit small difference from 20 to 60 min uptake time, indicating robustness for clinical use. Most clinically applied RGD-based PET tracers to date have been based on 18F, and...
somewhat higher SUV values have been reported [29], but our findings are comparable with other reports of 68Ga-based RGD tracers [32, 40–42]. No adverse events were identified during or after the tracer injections. Visualizing the Warburg effect by hyperpolarized [1-13C]pyruvate-MRSI resulted in [1-13C]lactate generation in most tumors. Tumor type dependence confirmed the pattern previously reported by our group [17, 20], with sarcomas tending to exhibit higher [1-13C]lactate to total 13C ratio compared to carcinomas (Fig. 5).

Tumor uptake patterns of [68Ga]Ga-NODAGA-RGD and [1-13C]lactate did not correspond in general. Only two of five tumors showed a significant voxel-wise positive correlation of [68Ga]Ga-NODAGA-RGD uptake and [1-13C]lactate imaging and one of five showed a significant negative correlation. As well, when comparing [68Ga]Ga-NODAGA-RGD uptake with the [1-13C]lactate ratio, no clear picture of spatial correspondence emerged. In agreement with this quantitative correlation analysis (Table 2), the overall lack of similarity of uptake patterns is also qualitatively apparent in Fig. 3, underscoring individual tumor heterogeneity and phenotype. Previous hyperPET reports from our group [16, 17] showed an overall spatial correlation between 13C-lactate and [18F]FDG uptake in tumors; however, it should be noted that tumor types in the present study were not matched to those earlier study.

We presented the basic hypothesis that as hypoxia-induced transcription factors induce both angiogenesis and glycolysis, the imaging modalities reflecting these processes might be correlated. However, the Warburg effect is independent of hypoxia, and tumors may have both hypoxic and non-hypoxic regions. These factors may explain the lack of overall spatial correspondence of [68Ga]Ga-NODAGA-RGD uptake with [1-13C]lactate generation, found in this study. This is in line with findings in earlier studies of FDG-PET and RGD-tracers [32, 43].

As visualized in Fig. 5, tumor voxel values of [68Ga]Ga-NODAGA-RGD uptake and [1-13C]lactate to total 13C ratio tend to group in clusters for each canine cancer patient. Alternatively stated, the intra-tumoral range of [68Ga]Ga-NODAGA-RGD uptake and [1-13C]lactate to total 13C ratio is smaller than the range of values across all tumors. The clusters of each tumor show little overlap for at least four of seven tumors. It is noteworthy that this separation of tumors occurs only in the combined parameter space of [68Ga]Ga-NODAGA-RGD uptake and [1-13C]lactate ratio. Tumor voxels from patient #1 have higher values of [1-13C]lactate to total 13C ratio than almost all other tumor voxels, but [68Ga]Ga-NODAGA-RGD uptake values are similar to tumor voxels from many other patients. Conversely, [68Ga]Ga-NODAGA-RGD uptake for patient #6 is higher than almost all other tumor voxels, but values for [1-13C]lactate to total 13C ratio are similar to tumor voxels from many other patients. For three of seven tumors shown in Fig. 5 (patients #4, #5, and #7), some overlap of both [68Ga]Ga-NODAGA-RGD uptake and [1-13C]lactate to total 13C ratio appears, with relatively small values of both

### Table 2

| Patient | # voxels | (lac-RGD) | (ratio-RGD) | Comments |
|---------|----------|-----------|-------------|----------|
|         |          | $r$       | $r^2$       | $p$      |          | $r$       | $r^2$       | $p$      |          |
| 1       | 13       | -0.0867   | 0.00751     | 0.7783   | 0.1661   | 0.0276   | 0.5877     |          |          |
| 2       | 14       | 0.5233    | 0.274       | 0.0548   | 0.5921   | 0.351    | 0.0257*    | Poor signal quality |
| 3       | 8        | 0.7562    | 0.571       | 0.0299*  | 0.0337   | 0.00114  | 0.9369     |          |          |
| 4       | 11       | -0.628    | 0.394       | 0.0386*  | 0.1411   | 0.0199   | 0.6791     | Negative lactate correlation |
| 5       | 3        | 0.9836    | 0.967       | 0.1154   | -0.7598  | 0.577    | 0.4506     | Too few voxels |
| 6       | 39       | 0.5876    | 0.345       | 0.0001*  | 0.7345   | 0.539    | 0.0001*    |          |
| 7       | 14       | -0.0893   | 0.00797     | 0.7615   | -0.5703  | 0.325    | 0.0332*    |          |

![Image](Fig5.png)
modalities ($^{68}$Ga-NODAGA-RGD uptake approximately 0.3–0.7 SUV and lactate ratio approximately 0.1–0.3). These tumors appear to have follicular morphology, an area of central necrosis, and a necrotic colloid core, respectively. The tumor voxels with $^{68}$Ga-NODAGA-RGD uptake 0.3–0.7 SUV and lactate ratio 0.1–0.3 could then overall be expected to represent regions with a relatively low number of active tumor cells. A single voxel from patient #1 also has a $^{68}$Ga-NODAGA-RGD uptake and lactate ratio value in this overlap region and covers a possible biopsy cavity (Fig. 1).

The data of Fig. 5 may be interpreted as follows: The combined molecular imaging of angiogenesis and deregulated tumor cell energy metabolism appears to characterize distinct cancer phenotypes, which may be of great importance for clinical therapeutic decision making. Further studies are warranted to determine if this imaging paradigm can aid in histopathological tumor characterization.

Clinical translation of hyperpolarized $[1-^{13}C]$pyruvate-MRSI into human patients is gaining momentum [44, 45]. Around the world, important experience is starting to emerge [46–48]. While most studies using hyperpolarized tracers are performed in a radiological (MR only) setting, we believe there lies an increased value of molecular imaging when combining with other modalities, such as PET. As we see indications of in this present study, the combination of modalities can provide additional information, making a combined examination more informative than if each were obtained separately. This is in line with other research groups, that are currently also pursuing the paradigm of complementary diagnostics in practice [16, 49].

The present study has some limitations. Imaging of canine cancer patients with spontaneous tumors is superior to cancer xenograft models in many regards, especially with respect to natural vasculature and intact immune system response. On the other hand, recruitment of this patient group limits the options of controlling treatment and cancer types, resulting in the mixed group of tumors. Even large animals must be anesthetized during the examination to avoid motion errors. Anesthesia can influence $[1-^{13}C]$pyruvate-MRSI [50] and perhaps also $^{68}$Ga-NODAGA-RGD-PET, although less likely, as this passive interaction is receptor-mediated. This limitation should be taken into consideration during clinical translation.

The limited spatial resolution of both PET and in particular $^{13}C$ MRSI implies that tumor heterogeneity on the millimeter scale is not captured. The importance of this in the context of therapeutic management is not known. As seen for patient #1 (Fig. 1), the small areas of necrosis visualized by anatomical MRI are hardly reflected in the spatial heterogeneity of the $^{13}C$ MRSI. Still, the tumor heterogeneity of patient #4 (Fig. 4) is sufficiently reflected in both imaging modality measures to both visually and quantitatively conclude that uptake patterns of $^{68}$Ga-NODAGA-RGD and $[1-^{13}C]$lactate to total $^{13}C$ ratio do not correspond. Current technical developments of both PET and $^{13}C$ MRSI acquisition schemes will improve image resolution [44].

The $^{13}C$ metabolite maps are additionally affected by the MR surface coil profile, as seen for patient #6 (Fig. 4(6d)). This effect is mitigated by using the $[1-^{13}C]$lactate to total $^{13}C$ ratio as a measure, hence the focus on $[1-^{13}C]$lactate to total $^{13}C$ ratio for the comparisons to $^{68}$Ga-NODAGA-RGD uptake in the present work. Further development in acquisition hardware and sequences are needed to overcome this limitation. Finally, the interpretations of the combined imaging of energy metabolism and angiogenesis put forward here would benefit from postoperative histological verification as performed by Bachawal et al. [16].

In conclusion, we demonstrated that combined molecular imaging of angiogenesis by $^{68}$Ga-NODAGA-RGD-PET and deregulated tumor metabolism by $[1-^{13}C]$pyruvate-MRSI is feasible in canine cancer patients with spontaneous tumors. RGD uptake and $[1-^{13}C]$lactate generation had no overall correspondence, neither spatially nor across patients. As well, in combination (but not separately) of $^{68}$Ga-NODAGA-RGD-PET and $[1-^{13}C]$pyruvate-MRSI showed a distinct clustering of tumor voxel values. Overall, the results suggest that $^{68}$Ga-NODAGA-RGD-PET and $[1-^{13}C]$pyruvate-MRSI may provide complementary information indicating that the non-invasive hyperPET combined imaging of angiogenesis and glycolysis is able to aid in cancer phenotyping. This may lead to options for improved treatment by tailoring medication combinations to the individual patient.

Acknowledgments The authors are grateful to the John and Birthe Meyer Foundation for the donation of the Siemens mMR hybrid PET/MR system to Rigshospitalet. The work could not have been done without the help of technologists Karin Stahr, Marianne Federspiel, and radiologist Jakup Poulsen. Finally, a big thanks to veterinary technicians Mette Hedelund Rasmussen and Line Bratajka Gaarsdahl for taking great care of the patients. Jacob Madsen and the radiochemistry team is gratefully acknowledged for production of the PET tracer.

Funding This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements no. 670261 (ERC Advanced Grant) and 668532 (Click-It), the Lundbeck Foundation, the Novo Nordisk Foundation, the Innovation Fund Denmark, the Danish Cancer Society, Arvid Nilsson Foundation, Svend Andersen Foundation, the Neye Foundation, the Research Foundation of Rigshospitalet, the Danish National Research Foundation (grant 126), the Research Council of the Capital Region of Denmark, the Danish Health Authority, and Research Council for Independent Research.

Compliance with ethical standards All animal procedures were approved by the Ethics and Administrative Committee, Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen. The datasets generated during the current study are available from the corresponding author on reasonable request.
Conflict of interest  The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Brustugun OT, Møller B, Helland Å. Years of life lost as a measure of cancer burden on a national level. Br J Cancer. 2014;111:1014–20. https://doi.org/10.1038/bjc.2014.364.

2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.

3. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30. https://doi.org/10.1085/jgp.8.6.519.

4. Ardenkjær-Larsen JH, Leach AM, Clarke N, Urbań J, Anderson D, Skloss TW. Dynamic nuclear polarization polarizer for sterile use intent. NMR Biomed. 2011;24:927–32. https://doi.org/10.1002/nbm.1682.

5. Zaccagna F, Grist JT, Deen SS, Woitek R, Lechermann LM, McLean MA, et al. Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism. Br J Radiol. 2018;91:20170688. https://doi.org/10.1259/bjr.20170688.

6. Wang ZJ, Oehliger MA, Larson PEZ, Gordon JW, Bok RA, Slater J, et al. Hyperpolarized (13)C MRI: state of the art and future directions. Radiology. 2019;182391. https://doi.org/10.1148/radiol.2019182391.

7. Gallagher FA, Woitek R, McLean MA, Gill AB, Manzano Garcia R, Provencenzo E, et al. Imaging breast cancer using hyperpolarized carbon-13 MRI. Proc Natl Acad Sci U S A. 2020; https://doi.org/10.1073/pnas.1913841100.

8. Ardenkjær-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003;100:10158–63. https://doi.org/10.1073/pnas.1733835100.

9. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: non-invasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–15. https://doi.org/10.1158/0008-5472.CAN-08-0749.

10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33. https://doi.org/10.1126/science.1160809.

11. Gutte H, Hansen AE, Johannesen HH, Clemmensen AE, Ardenkjær-Larsen JH, Nielsen CH, et al. The use of dynamic nuclear polarization C-13-pyruvate MRS in cancer. Am J Nucl Med Mol Imaging. 2015;5:548–60.

12. Gallagher FA, Bohdiek SE, Kettunen MI, Lewis DY, Soloviev D, Brindle KM. Hyperpolarized 13C MRI and PET: in vivo tumor biochemistry. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011;52:1333–6. https://doi.org/10.2967/jnumed.110.085258.

13. Cho A, Lau JYC, Geraghty BJ, Cunningham CH, Keshari KR. Noninvasive interrogation of cancer metabolism with hyperpolarized (13)C MRI. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58:1201–6. https://doi.org/10.2967/jnumed.116.182170.

14. Tran M, Latifoltotjar A, Neves JB, Papoutsaki MV, Gong F, Comment A, et al. First-in-human in vivo non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinoma. BJR Case Rep. 2019;5: https://doi.org/10.1259/bjcr.20190003.

15. Gutte H, Hansen AE, Henriksen ST, Johannesen HH, Ardenkjær-Larsen J, Vignaud A, et al. Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. Am J Nucl Med Mol Imaging. 2015;5:38–45.

16. Bachaval SV, Park JM, Valluru KS, Loft MD, Felt SA, Vilches-Moure JG, et al. Multimodality hyperpolarized C-13 MRS/PET/multiparametric MR imaging for detection and image-guided biopsy of prostate cancer: first experience in a canine prostate cancer model. Mol Imaging Biol. 2019; https://doi.org/10.1007/s11307-018-1235-6.

17. Gutte H, Hansen AE, Larsen MM, Rahbek S, Henriksen ST, Johannesen HH, et al. Simultaneous hyperpolarized 13C-pyruvate MRI and 18F-FDG PET (HyperPET) in 10 dogs with cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56:1786–92. https://doi.org/10.2967/jnumed.115.156364.

18. Gutte H, Hansen AE, Larsen MM, Rahbek S, Johannesen HH, Ardenkjær-Larsen J, et al. In vivo Phenotyping of tumor metabolism in a canine cancer patient with simultaneous (18)F-FDG-PET and hyperpolarized (13)C-pyruvate magnetic resonance spectroscopic imaging (hyperPET): mismatch demonstrates that FDG may not always reflect the Warburg effect. Diagnostics (Basel). 2015;5:287–9. https://doi.org/10.3390/10.02.24.

19. Hundshammer C, Braeuer M, Muller CA, Hansen AE, Schillina M, Duwel S, et al. Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized (13)C-MRSI. Theranostics. 2018;8:4765–80. https://doi.org/10.7150/thno.25162.

20. Hansen AE, Gutte H, Holst P, Johannesen HH, Rahbek S, Clemmensen AE, et al. Combined hyperpolarized (13)C-pyruvate MRS and (18)F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients. Eur J Radiol. 2018;103:6–12. https://doi.org/10.1016/j.ejrad.2018.02.028.

21. Desgrosellier JS, Cheshire DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22. https://doi.org/10.1038/nrc2748.

22. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816–26. https://doi.org/10.1038/nrm1490.

23. Danhier F, Le Breton A, Prevat V. RGD-based strategies to target alpha(v)beta3 integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961–73. https://doi.org/10.1021/mp3002733.

24. Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, Mysetczky R, El-Ali HH, Madsen J, et al. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E(c(RGDyK))2 and (64)Cu-NODAGA-E(c(RGDyK))2: in vivo imaging studies in human xenograft tumors. Nucl Med Biol. 2014;41:259–67. https://doi.org/10.1016/j.nucmedbio.2013.12.003.

25. Oxboel J, Schjoeth-Eskesen C, El-Ali HH, Madsen J, Kjaer A. (64)cu-NODAGA-c(RGDyK) is a promising new angiogenesis PET tracer: correlation between tumor uptake and integrin alpha(V)beta3 expression in human neuroendocrine tumor
38. Schramm G, Langner J, Hofheinz F, Petr J, Lougovski A, Beuthien-Comment A, Merritt ME. Hyperpolarized magnetic resonance as a clinical tool in oncology. Eur J Nucl Med Mol Imaging. 2020;47:2119–24. doi:https://doi.org/10.1007/s00259-020-05152-8.

39. Vincent RD, Neelin P, Khalili-Mahani N, Janke AL, Fonov VS, Robbins SM, et al. MINC 2.0: a flexible format for multi-modal images. Front Neuroinform. 2016;10:35. doi:https://doi.org/10.3389/fninf.2016.00035.

40. Haubner R, Finkenstedt A, Steglmayr A, Rangger C, Decristoforo C, Zoller H, et al. [(68)Ga]NODAGA-RGD—metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Eur J Nucl Med Mol Imaging. 2016;43:2005–13. https://doi.org/10.1007/s00259-016-3396-3.

41. Kang F, Wang Z, Li G, Wang S, Liu D, Zhang M, et al. Inter-heterogeneity and intra-heterogeneity of alphavbeta3 in non-small cell lung cancer and small cell lung cancer patients as revealed by (68)Ga-RGD2 PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:1520–8. https://doi.org/10.1007/s00259-017-3696-2.

42. Provost C, Rozenblum-Beddok L, Nataf V, Merabtieme F, Prignon A, Talbot J-N. [(68)Ga]RGD versus [(18)F]FDG PET imaging in monitoring treatment response of a mouse model of human Glioblastoma tumor with Bevacizumab and/or Temozolomide. Mol Imaging Biol. 2018;21:297–305. https://doi.org/10.1007/s11307-018-1224-9.

43. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin alphavbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9. https://doi.org/10.2967/jnumed.107.045864.

44. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, et al. Hyperpolarized (13)C MRI: path to clinical translation in oncology. Neoplasia. 2019;21:1–16. https://doi.org/10.1016/j.neo.2018.09.006.

45. Ardenkjaer-Larsen JH, Hyperpolarized MR. What’s up doc? J Magn Reson. 2019; https://doi.org/10.1016/j.jmr.2019.07.017.

46. Grist JT, McLean MA, Riemer F, Schulte RF, Deen SS, Zaccagna F, et al. Quantifying normal human brain metabolism using hyperpolarized [1-(13)C]pyruvate and magnetic resonance imaging. Neuroimage. 2019;189:171–9. https://doi.org/10.1016/j.neuroimage.2019.01.027.

47. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(13)C]pyruvate. Sci Transl Med. 2013;5:198ra08. doi:https://doi.org/10.1126/scitranslmed.3006070.

48. Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2018;80:864–73. https://doi.org/10.1002/mrm.27077.

49. Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, Lizak M, et al. EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn Reson Med. 2016;75:1637–47. doi:https://doi.org/10.1002/mrm.25696.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.